Objective To analysis the influence of neoadjuvant chemotherapy on VEGF mRNA expression in endometrial carcinoma. Methods 180 patients with endometrial carcinoma in the hospital who reached the project standard were enrolled, they were clinically diagnosed, and randomly divided into the observation group and the control group ( 90 cases in each group ). Patients in the control group using conventional chemotherapy after operation, the patients in the observation group received neoadjuvant chemotherapy. Comparing the two groups of patients after treatment, the clinical effect, incidence of adverse reactions, VEGF mRNA expression difference were observed and recorded. Results The general information in observation group and the control group patients such as age, course of disease, and staging have no statistical difference ( P > 0. 05 ); the total efficiency of patients in the observation group was significantly higher than that in control group ( 83. 3% vs 65.5% , P < 0. 05 ); VEGF mRNA expression of each stage in the observation group was lower than that in control group ( P < 0. 05 ), the total incidence of adverse reaction in observation group was significantly lower than that in control group ( 14.4% vs 34.4% , P <0. 05 ). Conclusion Neoadjuvant chemotherapy can effectively reduce the VEGF mRNA expression, improve its clinical efficacy, and reduce the occurrence of adverse reactions.%目的 分析新辅助化疗对子宫内膜癌血管内皮生长因子(VEGF) mRNA表达的影响.方法 子宫内膜癌患者180例均经临床确诊,随机分为观察组与对照组各90例.对照组患者使用常规术后化疗,观察组患者使用新辅助化疗,比较2组患者治疗效果、VEGF mRNA表达情况及不良反应发生率的差异.结果 观察组总有效率高于对照组(83.3% vs 65.5%,P<0.05),各个分期VEGF mRNA表达均低于对照组(P<0.05),总不良反应发生率明显低于对照组(14.4% vs 34.4%,P<0.05).结论 新辅助化疗可以有效降低VEGF mRNA的表达,并降低不良反应的发生,提高其临床疗效,值得在临床推广使用.
展开▼
